



## PRESS RELEASE

08 May 2025 | FOR IMMEDIATE RELEASE

### **Professor Shawn Chen appointed founding Editor-in-Chief of newly launched *ACS Nano Medicine***

*Singapore, 08 May 2025* — Professor Xiaoyuan (Shawn) Chen, Nasrat Muzayyin Chair Professor in Medicine and Technology, Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), has been appointed the founding Editor-in-Chief of [\*ACS Nano Medicine\*](#), a new peer-reviewed hybrid journal published by the American Chemical Society (ACS).

Set to begin accepting submissions in June 2025 and publish its inaugural issue in January 2026, *ACS Nano Medicine* will showcase significant research breakthroughs at the intersection of nanoscience, medicine, biology, chemistry, and materials. The journal aims to serve as a leading platform for research that applies nanotechnology to clinical diagnosis and therapeutics.

“Nanomedicine is unlocking new frontiers in the treatment of diseases once deemed untreatable, propelling us closer to the era of truly personalised medicine. I am energised to lead a journal dedicated to spotlighting the most transformative advances in the nanomedicine field,” said Prof Chen. “My vision is to catalyse collaboration and accelerate knowledge exchange across the global nanomedicine community, synergising with the work underway at NUS Medicine’s Nanomedicine Translational Research Programme.”

Prof Chen brings extensive experience and leadership to the role. In addition to directing the Nanomedicine Translational Research Programme and serving as Research Director at the Clinical Imaging Research Centre at NUS Medicine, he has authored over 1,000 peer-reviewed publications with more than 160,000 citations.

His research spans molecular imaging, drug and gene delivery, radiopharmaceuticals, and nanomedicine, with a particular focus on clinically translatable theranostics. Notably, his therapeutic radiopharmaceutical,  $^{177}\text{Lu}$ -LNC1004, has received approval from regulatory agencies in the US, Singapore, and China for the treatment of advanced solid tumours.

Professor Chen previously served as the founding editor of *Theranostics* and holds editorial roles across several scientific journals, including *ACS Nano*, *Bioconjugate Chemistry*, and *Journal of Nuclear Medicine*, among others. His international standing in the field has been recognised by numerous awards, including the Michael J. Welch Award from the Society of Nuclear Medicine and Molecular Imaging (2019) and the JNB Trailblazer Award (2023). He was also recently inducted into Academia Europaea and European Academy of Sciences, and elected to the Singapore National Academy of Science.

---

For media enquiries, please contact:

**Shaun YEE**

Communications Executive,  
Yong Loo Lin School of Medicine,  
National University of Singapore

DID: +65 9012 1928

Email: [medv3719@nus.edu.sg](mailto:medv3719@nus.edu.sg)

## **About National University of Singapore (NUS)**

The National University of Singapore (NUS) is Singapore's flagship university, which offers a global approach to education, research, and entrepreneurship, with a focus on Asian perspectives and expertise. We have 16 colleges, faculties, and schools across three campuses in Singapore, with more than 40,000 students from 100 countries enriching our vibrant and diverse campus community. We have also established more than 20 NUS Overseas Colleges entrepreneurial hubs around the world.

Our multidisciplinary and real-world approach to education, research and entrepreneurship enables us to work closely with industry, governments, and academia to address crucial and complex issues relevant to Asia and the world. Researchers in our faculties, research centres of excellence, corporate labs and more than 30 university-level research institutes focus on themes that include energy; environmental and urban sustainability; treatment and prevention of diseases; active ageing; advanced materials; risk management and resilience of financial systems; Asian studies; and Smart Nation capabilities such as artificial intelligence, data science, operations research, and cybersecurity.

For more information on NUS, please visit <http://www.nus.edu.sg/>

## **About the NUS Yong Loo Lin School of Medicine (NUS Medicine)**

The NUS Yong Loo Lin School of Medicine is Singapore's first and largest medical school. Our enduring mission centres on nurturing highly competent, values-driven, and inspired healthcare professionals to transform the practice of medicine and improve health around the world.

Through a dynamic and future-oriented five-year curriculum that is inter-disciplinary and inter-professional in nature, our students undergo a holistic learning experience that exposes them to multiple facets of healthcare and prepares them to become visionary leaders and compassionate doctors and nurses of tomorrow. Since the School's founding in 1905, more than 12,000 graduates have passed through our doors.

In our pursuit of health for all, our strategic research programmes focus on innovative, cutting-edge biomedical research with collaborators around the world to deliver high impact solutions to benefit human lives.

The School is the oldest institution of higher learning in the National University of Singapore and a founding institutional member of the National University Health System. It is one of the leading medical schools in Asia and ranks among the best in the world (Times Higher Education World University Rankings 2025 by subject and the Quacquarelli Symonds (QS) World University Rankings by subject 2025).

For more information about NUS Medicine, please visit <https://medicine.nus.edu.sg/>